APOA1 and coronary artery disorder: Initially discovered in 1998 by Dinu and colleagues in patients with SLE, anti-apoA-1 IgG were found to be associated with a higher prevalence and incidence of coronary artery disease (CAD), independently of traditional CV risk factors in autoimmune and non-autoimmune settings6,12–16.